Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
48 hedge funds and large institutions have $71.1M invested in Dicerna Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 12 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
50% more capital invested
Capital invested by funds: $47.5M → $71.1M (+$23.6M)
9% less funds holding
Funds holding: 53 → 48 (-5)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$1.23M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$909K |
| 3 |
Renaissance Technologies
New York
|
+$871K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$327K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.01M |
| 2 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$1.12M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$883K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$797K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$183K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
51
A.R.T. Advisors
New York
| – | -$170K | -56,763 | Closed |
|
|
TC
52
TFS Capital
West Chester,
Pennsylvania
| – | -$91K | -30,429 | Closed |
|
53
Two Sigma Investments
New York
| – | -$90K | -30,134 | Closed |
|
|
AGM
54
Alpine Global Management
New York
| – | -$61K | -20,488 | Closed |
|
55
Squarepoint
New York
| – | -$49K | -16,300 | Closed |
|
|
LP
56
LMR Partners
London,
United Kingdom
| – | -$35K | -11,757 | Closed |
|
57
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$33K | -11,130 | Closed |
|
58
Jane Street
New York
| – | -$31K | -10,274 | Closed |
|
59
Barclays
London,
United Kingdom
| – | -$6K | -1,842 | Closed |
|
|
TRCT
60
Tower Research Capital (TRC)
New York
| – | -$4K | -1,220 | Closed |
|
DRNA Hedge Fund Activity: Q3 2016 in Review
48 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q3 2016, worth a combined $71.1M — up 50% from $47.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of DRNA and 7 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $1.23M. The largest seller was Wellington Management Group, exiting entirely with an estimated $2.01M sold.
- 48 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q3 2016, down from 53 in Q2 2016.
- Funds reported $71.1M of Dicerna Pharmaceuticals, Inc. stock for Q3 2016, up 50% quarter-over-quarter.
- 7 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q3 2016 and 12 closed out, a net change of -5 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q3 2016 was 683 Capital Management, an estimated $1.23M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q3 2016 was Wellington Management Group, an estimated $2.01M sold.
Based on aggregated 13F filings for Q3 2016.